September 3rd, 2014
FAME 2 at 2 Years: Better with Time?
CardioExchange Editors, Staff
The CardioExchange editors ask whether the 2-year findings from FAME 2 are more compelling than the 7-month findings.
September 4th, 2012
ESC Trials: The Best And The Worst
Larry Husten, PHD
Larry Husten is back from ESC and discussing two trials that exemplify how medicine is supposed to work, and one that exemplifies what can go wrong, especially when commercial interests are at stake.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?